Adding the clinical framing, because it changes how the question reads.

NicoleRaleigh said:

...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

stefan_berlin said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 8.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Genuinely useful, thank you. I had the facts and not the framework. Printing the relevant bit and taking it with me.

Clinical perspective, offered as context rather than as advice.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

CarlaRPh_TPA said:

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated…

Same pattern here, and in the same order.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.